Source: http://www.google.com/patents/US20020161307?ie=ISO-8859-1&dq=U.S.+Patent+
Timestamp: 2016-02-06 21:48:26
Document Index: 62033768

Matched Legal Cases: ['art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100', 'art 100']

Patent US20020161307 - Method and apparatus for predicting acute response to cardiac ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA method and apparatus for predicting acute response to cardiac resynchronization therapy is disclosed. The method can comprise measuring a first interval during an intrinsic systolic cycle and measuring a second interval during a stimulated systolic cycle. The acute response can be predicted by comparing...http://www.google.com/patents/US20020161307?utm_source=gb-gplus-sharePatent US20020161307 - Method and apparatus for predicting acute response to cardiac resynchronization therapyAdvanced Patent SearchPublication numberUS20020161307 A1Publication typeApplicationApplication numberUS 09/822,790Publication dateOct 31, 2002Filing dateMar 30, 2001Priority dateMar 30, 2001Also published asUS6766189, US7313433, US8170652, US20040162496, US20080097542Publication number09822790, 822790, US 2002/0161307 A1, US 2002/161307 A1, US 20020161307 A1, US 20020161307A1, US 2002161307 A1, US 2002161307A1, US-A1-20020161307, US-A1-2002161307, US2002/0161307A1, US2002/161307A1, US20020161307 A1, US20020161307A1, US2002161307 A1, US2002161307A1InventorsYinghong Yu, Jiang Ding, Julio Spinelli, Angelo AuricchioOriginal AssigneeYinghong Yu, Jiang Ding, Julio Spinelli, Angelo AuricchioExport CitationBiBTeX, EndNote, RefManReferenced by (63), Classifications (6), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetMethod and apparatus for predicting acute response to cardiac resynchronization therapy
[0031] While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims. DETAILED DESCRIPTION [0032] Various embodiments of the present invention will be described in detail with reference to the drawings, wherein like reference numerals represent like parts and assemblies throughout the several views. Reference to various embodiments does not limit the scope of the present invention, which is limited only by the scope of the claims attached hereto. [0033] The following discussion is intended to provide a brief, general description of a suitable method for predicting a patient's acute response to cardiac resynchronization therapy (“CRT”). As will be described in greater detail below, the method of the present disclosure predicts a patient's acute response to CRT by measuring and/or comparing an intrinsic cardiac depolarization period against a cardiac depolarization period that is induced by electrical stimulation at a particular site or combination of sites. As will become apparent from the discussion below in connection with the various drawings, the method of present disclosure has particularized applicability when measuring and/or comparing intrinsic ventricular depolarization against stimulation-induced ventricular depolarization. However, those having ordinary skill in the art will readily appreciate that the method of the present disclosure can be implemented using any suitable cardiac depolarization periods, such as, the period between the peak of ventricular depolarization to the end of ventricular depolarization, or other cardiac depolarization periods. [0034] In a preferred embodiment, the method of the present disclosure predicts a patient's acute response to CRT by evaluating the period of depolarization of the right and left ventricles 108, 112 (FIG. 1). The period of depolarization of the ventricles 108, 112 can be evaluated using, for example, an electrocardiogram (“ECG”). An ECG is generally a graphical depiction of the electrical depolarization or excitement of the heart 100 (FIG. 1) as electrical impulses spread through the heart 100 as described above. An exemplary ECG for an intrinsic systolic cycle is shown in FIG. 3A. Each portion of the ECG is typically given an alphabetic designation corresponding to a pre-determined period of electrical depolarization or excitement. For example, the portion of the ECG that represents atrial depolarization is commonly referred to as the P-wave. Similarly, the portion of the ECG that represents ventricular depolarization is commonly referred to as the QRS complex comprising, for example, a Q-wave, a R-wave, and a S-wave. Moreover, the portion of the ECG that represents ventricular recovery or repolarization is commonly referred to as the T-wave (not shown). [0035] Each period of electrical depolarization or excitement represented on the ECG shown in FIG. 3A corresponds to a period of muscular activation within the heart 100 (FIG. 1). FIGS. 4A-4C are schematic illustrations depicting the various periods of muscular activation within the heart 100. Moreover, as shown in FIGS. 4A-4C, the ECG data can be monitored using any suitable electrocardiographic device 150, such as, a surface electrocardiographic device or an intracardiac device. FIG. 4A is a schematic illustration showing the period of atrial activation in response to electrical impulses initiated at the sinoatrial node 120 (corresponding to the P-wave portion of the ECG as discussed above). After electrical impulses spread from the sinoatrial node 120, the muscle tissues of the right and left atriums 106, 110 contract to pump blood into the right and left ventricles 108, 112, respectively. FIG. 4B is a schematic illustration showing the period of a ventricular depolarization in response to electrical impulses initiated at the atrioventricular node 122 and spread through the ventricles 108, 112 (corresponding to the QRS portion of the ECG as discussed above). After electrical impulses spread from the atrioventricular node 122, the muscle tissues of the right and left ventricles 108, 112 contract to pump blood to the lungs and throughout the body, respectively. FIG. 4C is a schematic illustration showing ventricular recovery or repolarization (corresponding to the T-wave portion of the ECG as discussed above). During ventricular repolarization, the membrane potential of the muscle cells reverse polarity and return to their resting state, thereby, causing the ventricles to relax. [0036] An ECG of a patient's heart can be used to assess cardiac performance by validating the existence of cardiac abnormalities, such as, arrhythmias evinced by an abnormally fast heart rate (e.g., tachycardia), an abnormally slow heart rate (e.g., bradycardia), or a normal rate but the depolarization is abnormally propagated (e.g., ectopic, or conduction system defect). The existence of an arrhythmia typically indicates that the heart's rhythm initiation and/or conduction system is functioning abnormally. Since CRT can be used, among other applications, to treat abnormal electrical conduction, prior to treating a patient using CRT, it is preferable to evaluate whether the heart's 100 (FIG. 1) conduction system is normal or abnormal. In one possible embodiment, the heart's ventricular conduction system can be assessed by analyzing the duration of ventricular depolarization. In particular, the duration of ventricular depolarization in patients having a normal conduction system can generally be characterized as being less than or equal to about 80 milliseconds. By “normal,” it is generally meant that ventricular depolarization within the heart 100 occurs synchronously as described above. Conversely, the duration of ventricular depolarization in patients having an abnormal conduction system can generally be characterized as being greater than about 80 milliseconds. By “abnormal,” it is generally meant that ventricular depolarization within the heart 100 occurs asynchronously or in stages. [0037] As discussed above, patients having an abnormal conduction system can potentially benefit from CRT. In particular, CRT can be used to deliver electrical stimulation to portions of the heart 100 (FIG. 1) to resynchronize the heart's activation, thereby, improving the efficiency of atrial and ventricular contractions necessary to circulate blood throughout the body. The amount of benefit derived from CRT, however, typically varies depending upon the severity of the abnormality of the heart's conduction system. Identification of patients that can benefit from CRT can be readily performed using, for example, the duration of ventricular depolarization (e.g., the width of the QRS complex). For example, if the duration of ventricular depolarization is greater than 120 milliseconds, it is generally believed that the patient can be considered as a possible candidate for CRT. If the duration of ventricular depolarization is greater than about 120 milliseconds, but less than about 150 milliseconds, it is generally believed that the patient can receive some benefit from CRT. Similarly, it is generally believed that a patient having a ventricular depolarization duration greater than about 150 milliseconds will receive significant benefit from CRT. [0038] After the patient has been identified as being a possible candidate for CRT, the site for delivering the CRT stimuli (e.g., the electrical impulses) can be chosen. While many locations are contemplated, the stimulation site for delivering the CRT stimuli can be any suitable location within the coronary circulation system (e.g., the system of arteries and veins supplying/removing the heart 100 with oxygen-rich/oxygen-depleted blood), such as, a coronary artery or coronary vein. In a preferred embodiment, however, the stimulation site for delivering the CRT stimuli is within a coronary vein, such as, the Great Cardiac Vein. Moreover, the location of the CRT stimulation site is generally selected based upon the severity and/or location of the blockage within the conduction system. [0039] The CRT stimuli is preferably delivered at a location within a coronary blood vessel such that the stimulation-induced depolarization is synchronized with the intrinsic depolarization. For example, as shown in FIG. 2, with respect to the right ventricle 108, the CRT stimuli can be provided at the septum wall 130, a right ventricle anterior location 131, a right ventricle lateral wall location 133, or a right ventricle posterior location (not shown) opposite the anterior location 131. Similarly, with respect to the left ventricle 112, the CRT stimuli can be provided at the septum wall 130, a left ventricle anterior location 132, a left ventricle lateral wall location 134, or a left ventricle posterior location (not shown) opposite the anterior location 132. Thus, for example, if the conduction system is blocked within the Right Bundle Branch 126, the CRT stimuli can be provided at a lateral location, such as, within a lateral vein (not shown) at the lateral heart wall 133 of the right ventricle 108. Similarly, if the conduction system is blocked within the Left Bundle Branch 128, the CRT stimuli can be provided at a lateral location, such as, within a lateral vein (not shown) at the lateral heart wall 134 of the left ventricle 112. Alternatively, if the conduction system is blocked within both the Right Bundle Branch 126 and the Left Bundle Branch 128, the CRT stimuli can be provided at the septum wall 130, at the right ventricle lateral wall 133 and/or at the left ventricle lateral wall 134. In any event, one having ordinary skill in the art will readily appreciate that any suitable stimulation site or combinations of stimulation sites for delivering the CRT stimuli can be chosen such that the stimulation-induced depolarization is synchronized with the intrinsic depolarization, or with other CRT stimuli in case of multiple-site stimulation configurations. [0040] Once a suitable stimulation site(s) has been identified, it is desirable to validate whether the selected stimulation site(s) will produce a positive hemodynamic response prior to completion of the procedure. To accomplish this, the present disclosure provides a method for predicting acute response to CRT for a selected stimulation site or combination of sites through assessment of a patient's conduction system. In particular, the method of the present disclosure predicts acute responses to CRT by comparing the percent change in duration between a first interval during an intrinsic systolic cycle and a second interval during a stimulated systolic cycle. [0041] In one possible embodiment, the first interval can be the duration of a patient's intrinsic ventricular depolarization while the second interval can be the duration of the patient's ventricular depolarization induced by the delivery of the CRT stimuli at the selected stimulation site(s). As shown in FIG. 3A, the duration of the patient's intrinsic ventricular depolarization is the QRS complex width WB measured from normal intrinsic heart beats. Similarly, as shown in FIG. 3B, the duration of the patient's stimulation-induced ventricular depolarization is the QRS complex width WS measured after ventricular stimulation. Accordingly, the method of the present disclosure can predict acute responses to CRT by assessing the percent change in intrinsic QRS complex width (e.g., WB) and stimulated QRS complex width (e.g., WS). In one possible embodiment, the percent change in QRS complex width can be compared to a threshold value to predict whether a selected stimulation site or combination of sites will provide a positive hemodynamic response to CRT. The phrase “threshold value” generally refers to a pre-determined value that can be used to classify the selected stimulation site(s) as responding (e.g., a stimulation site(s) that is likely to provide a positive hemodynamic response to CRT) or non-responding (e.g., a stimulation site(s) that is unlikely to provide a positive hemodynamic response to CRT). The following expression can, therefore, be used to predict whether a given stimulation site or combination of sites can be used to provide a beneficial or positive hemodynamic response to CRT. Stimulation   Site  :  Responding  :   W S - W B W S < THRESHOLD VALUE  Non  -  responding  :   W S - W B W S ≥ THRESHOLD VALUE [0042] The QRS complex width can be measured using any suitable electrocardiographic device 150 (FIGS. 4A-4C). In one possible embodiment, the electrocardiographic device 150 is a surface ECG device. However, one having ordinary skill in the art will readily appreciate that the electrocardiographic device 150 can be an intracardiac device. In one possible embodiment, the QRS complex width can be taken as the maximum of a 12-lead ECG. The intrinsic QRS complex width WB can be evaluated as a function of one or more normal intrinsic systolic cycles (e.g., sinus beats). For example, in one possible embodiment, the intrinsic QRS complex width WB can be averaged over 16 normal instrinsic systolic cycles. In this embodiment, the systolic cycles used to measure the intrinsic QRS complex width WB can be selected consecutively. However, one having ordinary skill in the art will readily appreciate that the systolic cycles used to measure the intrinsic QRS complex width WB can be non-consecutive. [0043] The stimulated QRS complex width WS is preferably measured during ventricular stimulation at a short atrioventricular delay (“AVD”). The atrioventricular delay is generally considered to be the length of time between an atrial sensed (or stimulated) event P and the delivery of a ventricular output pulse V (FIG. 3B). Further, by “short atrioventricular delay,” it is generally meant that a ventricular stimulation will be delivered at some fraction of the overall intrinsic AV interval. For example, in one possible embodiment, the short AVD used to evaluate the stimulated QRS complex is typically less than about one-half (e.g., 0.5) of the intrinsic AV interval and, preferably, can range from an atrial sensed or stimulated event (e.g., the initiation of the AV interval or zero AVD) to about 0.25 of the intrinsic AV interval. In one embodiment of the present disclosure, the stimulated QRS complex width WS can be evaluated as a function of one or more stimulated systolic cycles. For example, the stimulated QRS complex width WS can be averaged over 16 stimulated systolic cycles between 0 AVD and 0.25 AVD. [0044] As discussed above, a threshold value can be used to classify selected stimulation sites as being responding (e.g., a stimulation site(s) that is likely to provide a positive hemodynamic response to CRT) or non-responding (e.g., a stimulation site(s) that is unlikely to provide a positive hemodynamic response to CRT). Clinical studies were undertaken to establish a suitable threshold value for classifying a given stimulation site as being either responding or non-responding. In particular, the threshold value can be determined from the relationship between percent change in ventricular pressure derivative (LV+dp/dt) and percent change in QRS complex width as discussed above. The results of the clinical evidence are shown in FIGS. 5 and 6. In the embodiment illustrated in FIG. 5, the percent change between stimulation and intrinsic baseline in the ventricular pressure derivative (LV+dp/dt) is measured at the left ventricle. Fifteen stimulation sites from twelve patients were evaluated during the clinical analysis summarized in FIG. 5. In this analysis, there were eight responding sites and seven non-responding sites. The stimulated QRS complex width WS for each site was averaged over 8 beats across two short AV delays (e.g., �th of the patient's intrinsic AV interval). Similarly, in the embodiment illustrated in FIG. 6, the mean percentage improvement in left ventricular pressure derivative (LV+dp/dt) is plotted against percent change in duration of ventricular depolarization (calculated in the same manner as the results shown in FIG. 5) for different response types. The dotted line in FIGS. 5 and 6 identifies a threshold value can be established to separate the responding stimulation sites and the non-responding stimulation sites. Using the results shown in FIGS. 5 and 6, a range for the threshold value can be estimated between about 10-25 percent, typically about 15-20 percent, and preferably about 18 percent of the change in QRS complex width. In so doing, the present disclosure provides a simple method that can be easily implemented to predict acute hemodynamic response to CRT for a given stimulation site or combination of sites. [0045] [0045]FIGS. 7A and 7B illustrate an alternative embodiment for predicting acute response to CRT for selected stimulation sites. In particular, a patient's acute response to CRT can be predicted by analyzing the trends in more than one AV delay evaluated as a function of percent change in QRS width. Variations in the percent change in QRS width across multiple AV delay values typically indicates that the selected stimulation site(s) are non-responding. Accordingly, the patient will be unlikely to derive an acute hemodynamic benefit from CRT using the selected stimulation site(s). Conversely, small variations or no variations in QRS width across multiple AV delay values typically indicates that the selected stimulation site(s) are responding. Thus, for example, as shown in FIG. 7A, if the percent change in QRS complex width for a selected stimulation site(s) is variable as the AV delay is varied, the selected stimulation site(s) can be generally considered non-responding. As shown in FIG. 7B, if the percent change in QRS complex width for a selected stimulation site(s) is not varying as the AV delay is varied, the selected stimulation site(s) can be generally considered responding. While the graphs shown in FIGS. 7A and 7B illustrate the percent change in QRS width across five AV delays, one having ordinary skill in the art will readily appreciate that the number of AV delays can vary to include more AV delay values or less AV delay values. [0046] The method of the present disclosure can be implemented using a CRT system comprising various devices and/or programmers, including implantable or external CRT devices and/or programmers, such as, a CRT tachy or brady system comprising, for example, a programmable pulse generator capable of transmitting electrical stimulation pulses. Accordingly, in addition to the above-described embodiments, the method of the present disclosure can be implemented as logical operations controlling a suitable CRT device and/or programmer. The logical operations of the present disclosure can be implemented: (1) as a sequence of computer implemented steps running on the CRT device and/or programmer; and (2) as interconnected machine modules within the CRT device and/or programmer. The implementation is a matter of choice dependant on the performance requirements of the CRT device and/or programmer implementing the method of the present disclosure and the components selected by or utilized by the users of the method. Accordingly, the logical operations making up the embodiments of the method of the present disclosure described herein can be referred to variously as operations, steps, subsystems, or modules. [0047] One possible embodiment of a CRT system 300 that can be used to implement the method of the present disclosure is illustrated in FIG. 10. As shown in FIG. 10, the CRT system 300 generally comprises a programming device 301 (e.g., pulse generator) that can be used to regulate stimulation pulses that are delivered to the heart 100. In one possible embodiment, the heart 100 is connected to various leads 320 having electrodes (not shown) and terminal pins (not shown) that can connect the heart 100 to the CRT system 300. The various leads 320 connecting the heart 100 to the CRT system 300 will be described in greater detail below. [0048] The programmer 301 can regulate the stimulation pulses delivered to the heart 100 using, for example, a telemetry module 302. In one possible embodiment, the telemetry module 302 is unidirectional (e.g., capable of allowing the programmer 301 to receive data). However, in an alternative embodiment, the telemetry module 302 can be bi-directional (e.g., capable of allowing the programmer 301 to receive and/or send data). The command input module 304 is configured to interpret the data received from the programmer 301 such that the stimulation pulses can be accurately distributed according to predetermined criteria, such as, the specific requirements of the patient being treated. A controller 306 can be used to control the specific instructions regarding the stimulation pulses delivered to the heart 100. In one possible embodiment, the controller 306 can be controlled manually. In an alternative embodiment, however, the controller 306 can be controlled automatically using, for example, feedback received from an intrinsic signal analyzer 338. Moreover, one having ordinary skill in the art will readily appreciate that the controller 206 and the programmer 301 can be combined into a single unit. The instructions from the controller 306 are received by an electrode switching and output circuitry module 308 that delivers the stimulation pulses to the appropriate lead 320 within the heart 100. [0049] As discussed above, the heart 100 is connected to the CRT system 300 using various lead 320. The various leads 320 are preferably configured to carry the CRT stimuli from the programmer 301 to the heart 100. Moreover, the various leads 320 can likewise operate in a demand mode, thereby, relaying intrinsic cardiac signals form the heart's 100 electrical conduction system back to one or more sense amplifiers 310, 312, 314, 316. In one possible embodiment, the various leads 320 comprise separate and distinct leads connecting the CRT system 300 to different portions of the heart 100. In particular, the various leads 320 can comprise a lead 322 connected to the right-side portion or pump 102 (FIG. 1) of the heart 100, including, for example, a right atrium lead 324 configured to operate with a right atrium amplifier 310 and a right ventricle lead 326 configured to operate with a right ventricle amplifier 312. Similarly, the various leads 320 can comprise a lead 327 connected to the left-side portion or pump 104 (FIG. 1) of the heart 100, including, for example, a first left ventricle lead 328 configured to operate with a first left ventricle amplifier 314 and a second left ventricle lead 330 configured to operate with a second left ventricle amplifier 316. [0050] As discussed above, the various leads 320 connected to the heart 100 can relay intrinsic cardiac signals form the heart's 100 electrical conduction system back to the one or more sense amplifiers 310, 312, 314, 316. The intrinsic cardiac signals processed by the sense amplifiers 310, 312, 314, 316 can be processed by an intrinsic signal analyzer 338. The intrinsic signal analyzer 338 generally can comprise an analysis module 340 that is configured to analyze the electrocardiographic information gathered using, for example, an intracardiac electrogram. However, as discussed above, the electrocardiographic information can be gathered using a surface ECG. After analysis of the electrocardiographic information, the stimulation site(s) can be evaluated by a validation module 342 in accordance with the method described above. A configuration module 344 can be used to make adjustments to the CRT system 300 based upon whether the validation module 342 determines the selected stimulation site(s) to be responding or non-responding as described above. [0051] Referring now to FIG. 8, a high-level flow chart summarizing the logical operations of the method of the present disclosure is shown. At operation 200, the patient is initially validated as a potential candidate for CRT. This can be accomplished, as discussed above, by comparing the patient's intrinsic QRS duration against predetermined criteria. At operation 202, the operator of the CRT device or programmer can select a suitable stimulation site within the patient's cardiac circulation system. Once the stimulation site is chosen, operation 204 validates the selected stimulation site as being either responding or non-responding as discussed above. [0052] [0052]FIG. 9 provides a more detailed flow chart summarizing the logical operations followed when validating the selected stimulation site(s) and, therefore, predicting whether the patient will derive an acute hemodynamic benefit from CRT applied at the selected site(s). In one possible embodiment, validation of the selected stimulation site(s) is accomplished by first measuring the intrinsic QRS complex width WB at operation 210. As discussed above, the intrinsic QRS complex width WB can be measured using a surface ECG and evaluated as a function of one or more normal intrinsic systolic cycles (e.g., sinus beats). After measuring the intrinsic QRS complex width WB, a stimulated QRS complex width WS can be measured at operation 212. The stimulated QRS complex width WS is preferably measured during ventricular stimulation at a short AV delay as discussed above. After measurement of the intrinsic QRS complex width WB and the stimulated QRS complex width WS, the percent change in QRS complex width can be calculated at operation 214. The percent change in QRS complex width can be compared against a pre-determined threshold value at operation 216 to predict whether the selected stimulation site(s) are responding (e.g., a stimulation site(s) that is likely to provide a positive hemodynamic response to CRT) or non-responding (e.g., a stimulation site(s) that is unlikely to provide a positive hemodynamic response to CRT). Furthermore, the selected stimulation site(s) can be classified according to its response type. [0053] [0053]FIG. 7C is a flow chart summarizing the logical operations of the alternative embodiment for predicting acute response to CRT for selected stimulation sites described above in connection with FIGS. 7A and 7B. In this embodiment and as described above, the acute response to CRT can be predicted by analyzing the trends in more than one AV delay evaluated as a function of percent change in QRS width. As shown in FIG. 7C, at operation 220, a first interval during an intrinsic systolic cycle can be measured over more than one atrioventricular delays. At operation 222, a second interval during a stimulated systolic cycle can be measured over each of the atrioventricular delay. In one possible embodiment, the first interval can be an intrinsic QRS complex (WB) measured during a non-stimulated systolic cycle and the second interval can be a stimulated QRS complex (WS) measured during a stimulated systolic cycle. Once the first and second intervals are measured at operations 220 and 222, the percent change in duration between the first and second intervals for each AV delay can be determined at operation 224. The acute response type (e.g., responding or non-responding) can be classified according to analysis of the trends in percent change in duration between the first and second intervals at operation 226. [0054] The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Those skilled in the art will readily recognize the various modifications and changes which may be made to the present invention without strictly following the exemplary embodiments illustrated and described herein, and without departing from the true spirit and scope of the present invention, which is set forth in the following claims. Referenced byCiting PatentFiling datePublication dateApplicantTitleUS7200439Jan 23, 2004Apr 3, 2007Proteus Biomedical, Inc.Method and apparatus for enhancing cardiac pacingUS7204798Jan 23, 2004Apr 17, 2007Proteus Biomedical, Inc.Methods and systems for measuring cardiac parametersUS7214189Sep 1, 2005May 8, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS7267649Jan 23, 2004Sep 11, 2007Proteus Biomedical, Inc.Method and system for remote hemodynamic monitoringUS7346393Jun 12, 2003Mar 18, 2008Cardiac Pacemakers, Inc.Implantable cardiac rhythm management system having multiple therapy modalitiesUS7363077Nov 9, 2004Apr 22, 2008Pacesetters, Inc.Adaptive timing interval control method for treating congestive heart failureUS7555340 *Apr 1, 2005Jun 30, 2009Cardiac Pacemakers, Inc.Electrogram morphology-based CRT optimizationUS7558626Apr 23, 2003Jul 7, 2009Medtronic, Inc.Cardiac resynchronization via left ventricular pacingUS7558628Jul 10, 2006Jul 7, 2009Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS7637867Mar 29, 2007Dec 29, 2009Proteus Biomedical, Inc.Methods for configuring implantable satellite effectorsUS7640060Mar 29, 2007Dec 29, 2009Proteus Biomedical, Inc.Implantable satellite effectorsUS7713194Mar 29, 2007May 11, 2010Proteus Biomedical, Inc.Methods for configuring satellite electrodesUS7713195Mar 29, 2007May 11, 2010Proteus Biomedical, Inc.Methods for controlling implantable satellite electrodesUS7738958Feb 28, 2007Jun 15, 2010Proteus Biomedical, Inc.Methods and apparatus for enhancing cardiac pacingUS7769451Apr 28, 2005Aug 3, 2010Medtronic, Inc.Method and apparatus for optimizing cardiac resynchronization therapyUS7787951May 2, 2006Aug 31, 2010Pacesetter, Inc.System and method for determining optimal stimulation sites based on ECG informationUS7930026Apr 25, 2003Apr 19, 2011Medtronic, Inc.Monitoring QRS complex to identify left ventricular dysfunctionUS7935056Mar 29, 2007May 3, 2011Proteus Biomedical, Inc.Intravascularly implantable integrated circuitsUS7983751Aug 9, 2006Jul 19, 2011Proteus Biomedical, Inc.Measuring conduction velocity using one or more satellite devicesUS8036743Mar 31, 2006Oct 11, 2011Proteus Biomedical, Inc.Automated optimization of multi-electrode pacing for cardiac resynchronizationUS8078276Jun 30, 2009Dec 13, 2011Cardiac Pacemakers, Inc.Electrogram morphology-based CRT optimizationUS8116866Jul 6, 2009Feb 14, 2012Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS8123684Nov 23, 2009Feb 28, 2012Proteus Biomedical, Inc.Methods for configuring implantable satellite effectorsUS8229557 *Mar 29, 2007Jul 24, 2012Cardiac Pacemakers, Inc.Estimating acute response to cardiac resynchronization therapyUS8352027Mar 13, 2008Jan 8, 2013Cardiac Pacemakers, Inc.Implantable cardiac rhythm management system having multiple therapy modalitiesUS8355784May 13, 2011Jan 15, 2013Medtronic, Inc.Dynamic representation of multipolar leads in a programmer interfaceUS8364265Jan 8, 2007Jan 29, 2013Cardiac Pacemakers, Inc.Method and apparatus for capture verification and threshold determinationUS8406880May 29, 2007Mar 26, 2013Cardiac Pacemakers, Inc.Template-based capture verification for multi-site pacingUS8412347Apr 29, 2009Apr 2, 2013Proteus Digital Health, Inc.Methods and apparatus for leads for implantable devicesUS8473069Feb 27, 2009Jun 25, 2013Proteus Digital Health, Inc.Integrated circuit implementation and fault control system, device, and methodUS8483829Sep 20, 2012Jul 9, 2013Medtronic, Inc.Dynamic representation of multipolar leads in a programmer interfaceUS8494631Aug 31, 2011Jul 23, 2013Medtronic, Inc.System and method for profiling a patients hemodynamic response based on heart soundsUS8700148Mar 29, 2007Apr 15, 2014Proteus Digital Health, Inc.Methods and apparatus for tissue activation and monitoringUS8700149 *May 24, 2012Apr 15, 2014Cardiac Pacemakers, Inc.Estimating acute response to cardiac resynchronization therapyUS8712549Dec 11, 2003Apr 29, 2014Proteus Digital Health, Inc.Method and system for monitoring and treating hemodynamic parametersUS8718770Oct 21, 2010May 6, 2014Medtronic, Inc.Capture threshold measurement for selection of pacing vectorUS8786049Jul 23, 2010Jul 22, 2014Proteus Digital Health, Inc.Solid-state thin-film capacitorUS9020596Jul 11, 2012Apr 28, 2015Cardiac Pacemakers, Inc.Management of fusion beat detection during capture threshold determinationUS20040215049 *Jan 23, 2004Oct 28, 2004Proteus Biomedical, Inc.Method and system for remote hemodynamic monitoringUS20040215249 *Apr 23, 2003Oct 28, 2004Giorgio CorbucciCardiac resynchronization via left ventricular pacingUS20040215254 *Apr 25, 2003Oct 28, 2004Willem BouteMonitoring QRS complex to identify left ventricular dysfunctionUS20040254483 *Jan 23, 2004Dec 16, 2004Proteus Biomedical, Inc.Methods and systems for measuring cardiac parametersUS20040254614 *Jun 12, 2003Dec 16, 2004Cardiac Pacemakers, Inc.Implantable Cardiac rhythm management system having multiple therapy modalitiesUS20060058588 *Sep 1, 2005Mar 16, 2006Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20060224198 *Apr 1, 2005Oct 5, 2006Yanting DongElectrogram morphology-based CRT optimizationUS20060241706 *Jul 10, 2006Oct 26, 2006Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS20070173896 *Mar 29, 2007Jul 26, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20070173897 *Mar 29, 2007Jul 26, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20070185537 *Mar 29, 2007Aug 9, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20070185549 *Mar 29, 2007Aug 9, 2007Proteus Biomedical, Inc.Methods and apparatus for tissue activation and monitoringUS20070219591 *Feb 28, 2007Sep 20, 2007Mark ZdeblickMethods and apparatus for enhancing cardiac pacingUS20070219593 *May 29, 2007Sep 20, 2007Cardiac Pacemakers, Inc.Template-based capture verification for multi-site pacingUS20080027289 *Mar 29, 2007Jan 31, 2008Proteus Biomedical, Inc.Implantable satellite effectorsUS20080097227 *Jul 27, 2007Apr 24, 2008Zdeblick Mark JMethod and system for remote hemodynamic monitoringUS20080221635 *Mar 13, 2008Sep 11, 2008Cardiac Pacemakers, Inc.Implantable cardiac rhythm management system having multiple therapy modalitiesUS20080243202 *Mar 29, 2007Oct 2, 2008Abhilash PatangayEstimating acute response to cardiac resynchronization therapyUS20090264949 *Oct 22, 2009Yanting DongElectrogram morphology-based crt optimizationUS20090270937 *Jul 6, 2009Oct 29, 2009Yonce David JMorphology-based optimization of cardiac resynchronization therapyUS20100121403 *Nov 7, 2008May 13, 2010Pacesetter, Inc.Identification of electro-mechanical dysynchrony with a non-cardiac resynchronization therapeutic deviceUS20120232607 *May 24, 2012Sep 13, 2012Abhilash PatangayEstimating acute response to cardiac resynchronization therapyUS20150290391 *Apr 15, 2014Oct 15, 2015Insulet CorporationMonitoring a physiological parameter associated with tissue of a host to confirm delivery of medicationWO2008121185A1 *Feb 15, 2008Oct 9, 2008Cardiac Pacemaker IncEstimating acute response to cardiac resynchronization therapyWO2015089002A1 *Dec 9, 2014Jun 18, 2015Medtronic, Inc.Noninvasive cardiac therapy evaluation* Cited by examinerClassifications U.S. Classification600/509International ClassificationA61N1/362, A61N1/368Cooperative ClassificationA61N1/3682, A61N1/3627European ClassificationA61N1/362CLegal EventsDateCodeEventDescriptionAug 20, 2001ASAssignmentOwner name: CARDIAC PACEMAKERS, INC., MINNESOTAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YU, YINGHONG;DING, JIANG;SPINELLI, JULIO;AND OTHERS;REEL/FRAME:012089/0145;SIGNING DATES FROM 20010716 TO 20010801Jan 22, 2008FPAYFee paymentYear of fee payment: 4Jan 28, 2008REMIMaintenance fee reminder mailedDec 21, 2011FPAYFee paymentYear of fee payment: 8Jan 6, 2016FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services